Your browser doesn't support javascript.
loading
ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
Xu, Tao; Zhang, Jian; Chen, Wei; Pan, Shengjing; Zhi, Xiao; Wen, Liang; Zhou, Yue; Chen, Bryan Wei; Qiu, Junyu; Zhang, Yun; Yang, Qi; Feng, Xinhua; Bai, Xueli; Liang, Tingbo.
Afiliación
  • Xu T; Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88 Jiefang Road, Hangzhou 310009, China.
  • Zhang J; Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88 Jiefang Road, Hangzhou 310009, China.
  • Chen W; Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88 Jiefang Road, Hangzhou 310009, China.
  • Pan S; Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88 Jiefang Road, Hangzhou 310009, China.
  • Zhi X; Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88 Jiefang Road, Hangzhou 310009, China.
  • Wen L; Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88 Jiefang Road, Hangzhou 310009, China.
  • Zhou Y; Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88 Jiefang Road, Hangzhou 310009, China.
  • Chen BW; Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88 Jiefang Road, Hangzhou 310009, China.
  • Qiu J; Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88 Jiefang Road, Hangzhou 310009, China.
  • Zhang Y; Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88 Jiefang Road, Hangzhou 310009, China.
  • Yang Q; Center for Immunology & Microbial Disease, Albany Medical College, ME-20547 New Scotland Ave., MC-151, Albany, NY 12208-3479, USA.
  • Feng X; Life Science Institute and Innovation Center for Cell Signaling Network, Zhejiang University, Hangzhou, China.
  • Bai X; Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88 Jiefang Road, Hangzhou 310009, China; Collaborative Innovation Center for Cancer Medicine, Zhejiang University, Hangzhou, China.
  • Liang T; Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88 Jiefang Road, Hangzhou 310009, China; Collaborative Innovation Center for Cancer Medicine, Zhejiang University, Hangzhou, China. Electronic address: liangtingbo@zju.edu
Cancer Lett ; 377(2): 140-8, 2016 07 28.
Article en En | MEDLINE | ID: mdl-27126361

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Quinasas / Proteínas Represoras / Doxorrubicina / Carcinoma Hepatocelular / Resistencia a Antineoplásicos / Transición Epitelial-Mesenquimal / Neoplasias Hepáticas / Antibióticos Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Lett Año: 2016 Tipo del documento: Article País de afiliación: China Pais de publicación: Irlanda

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Quinasas / Proteínas Represoras / Doxorrubicina / Carcinoma Hepatocelular / Resistencia a Antineoplásicos / Transición Epitelial-Mesenquimal / Neoplasias Hepáticas / Antibióticos Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Lett Año: 2016 Tipo del documento: Article País de afiliación: China Pais de publicación: Irlanda